Nurix Therapeutics is trading 5.2% down today at $23.40 as investors digest valuation and lock in gains following a sharp post-earnings and Roche-deal rally.
- The stock recently surged on a transformative $2.3 billion global collaboration with Roche for bexobrutide and positive Q2 updates.
- Today’s pullback appears to be a typical consolidation phase following major positive news rather than a reaction to new negative developments.